Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: Are they two different diseases?

被引:118
作者
Ghobrial, IM
Habermann, TM
Macon, WR
Ristow, KM
Larson, TS
Walker, RC
Ansell, SM
Gores, GJ
Stegall, MD
McGregor, CG
机构
[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Dept Pathol, Rochester, MN USA
[3] Mayo Clin, Dept Internal Med, Div Infect Dis, Rochester, MN USA
[4] Mayo Clin, Dept Internal Med, Div Gastroenterol & Hepatol, Rochester, MN USA
[5] Mayo Clin, Dept Internal Med, Div Nephrol, Rochester, MN USA
[6] Mayo Clin, Dept Surg, Div Transplantat Surg, Rochester, MN USA
关键词
posttransplant lymphoproliferative disorders; Epstein-Barr virus; lymphoma; early; late;
D O I
10.1097/01.TP.0000144335.39913.5C
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The objective of the authors' study was to characterize the clinical and pathologic differences between patients who develop posttransplant lymphoproliferative disorders (PTLD) early or late after transplantation and to assess the overall survival in these two groups. Methods. One hundred seven adult solid organ transplant patients were identified at the Mayo Clinic between December 1970 and May 2003. Results. Forty-nine patients developed PTLD within the first year (early PTLD, 1-11.8 months) and 58 patients developed PTLD after I year (late PTLD, 14 months-17 years). Patients with early PTLD more commonly had the following characteristics: positive Epstein-Barr virus (EBV) in situ hybridization status (P<0.0001), CD20-positive status (P=0.002), and involvement of the grafted organ (P=0.02). Overall survival did not differ between the two groups (P=0.25). PTLD may occur in two different settings with different characteristics. Conclusions. Early PTLD is more commonly EBV in situ hybridization-positive and CD20-positive, and more commonly involves the grafted organ.
引用
收藏
页码:244 / 247
页数:4
相关论文
共 21 条
  • [1] A RECENT DECREASE IN THE TIME TO DEVELOPMENT OF MONOMORPHOUS AND POLYMORPHOUS POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER
    ALFREY, EJ
    FRIEDMAN, AL
    GROSSMAN, RA
    PERLOFF, LJ
    NAJI, A
    BARKER, CF
    MONTONE, KT
    TOMASZEWSKI, JE
    CHMIELEWSKI, C
    HOLLAND, T
    ZMIJEWSKI, C
    DAFOE, DC
    [J]. TRANSPLANTATION, 1992, 54 (02) : 250 - 253
  • [2] ARMITAGE JM, 1991, J HEART LUNG TRANSPL, V10, P877
  • [3] Late onset post-transplantation lymphoproliferative disease of recipient origin following cytogenetic relapse and occult autologous haematopoietic regeneration after allogeneic bone marrow transplantation for acute myeloid leukaemia
    Au, WY
    Lie, AK
    Lee, CK
    Ma, SK
    Wan, TS
    Shek, TW
    Liang, R
    Kwong, YL
    [J]. BONE MARROW TRANSPLANTATION, 2001, 28 (04) : 417 - 419
  • [4] Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)
    Dharnidharka, VR
    Sullivan, EK
    Stablein, DM
    Tejani, AH
    Harmon, WE
    [J]. TRANSPLANTATION, 2001, 71 (08) : 1065 - 1068
  • [5] Expert Group on Renal Transplantation, 2002, NEPHROL DIAL TRANSPL, V17, P31
  • [6] GHOBRIAL IM, 2003, P AN M AM SOC CLIN, V22, P573
  • [7] GHOBRIAL IM, 2003, BLOOD, V102, pA329
  • [8] Harris NL, 1997, SEMIN DIAGN PATHOL, V14, P8
  • [9] HORWITZ SM, 1999, BLOOD S, V94, P10
  • [10] Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders
    Leblond, V
    Dhedin, N
    Bruneel, MFM
    Choquet, S
    Hermine, O
    Porcher, R
    Quoc, SN
    Davi, F
    Charlotte, F
    Dorent, R
    Barrou, B
    Vernant, JP
    Raphael, M
    Levy, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) : 772 - 778